In mid-February 2020, within the Oise (France) cluster, a case of COVID-19 disease caused by a SARS-CoV2 infection was described among the personnel of the Creail Air Force Base (BA110). This resulted in the beginning of an epidemic controlled by epidemiological measures. One month later, containment measures were taken at the national level, measures that also applied to BA110 personnel. These personnel, exposed to both the initial phase of the epidemic and national protection measures, represent an extremely interesting population for understanding the epidemiological dynamics of the virus, particularly at a time when France is lifting the containment measures. It becomes extremely important to understand the levers of viral spread in order to adjust the health measures to be maintained as best as possible. The main objective of this study is to determine the extent of virus diffusion in this highly circulating population, as evidenced by several identified cases of COVID-19.
Study Type
OBSERVATIONAL
Enrollment
1,146
The anti-SARS-CoV2 serological status will be measured on a blood sample collected at Day 0.
Epidemiological data will be collected in a questionnaire that will be filled by participants at Day 0 (Visit 1), after 3 months (Visit 2) and after 9 months (Visit 3). The questionnaire includes: * medical data (height, weight, smoking, history of intense stress); * socio-demographic data (age, gender, civil/military status, function/occupation, rank category, army, family status/home composition, housing conditions, etc.); * clinical data : history of symptoms suggestive of COVID-19 in the last 3 months, current symptoms suggestive of COVID-19; * use of care, hospitalization, work stoppage in the last 3 months; * contact with people who are symptomatic or proven COVID-19.
Serological controls and a serum neutralization test will be performed on blood samples collected 3 months (Visit 2) and 9 months (Visit 3) after Day 0, respectively.
24e antenne médicale de Creil
Creil, France
Proportion anti-SARS-CoV2 seropositive
The percentage of the study population with positive serological status will be determined. ELISA serology test will be used to detect anti-SARS-CoV2 antibodies (IgG and IgM) at Day 0
Time frame: Day 0
Proportion of asymptomatic anti-SARS-CoV2 seropositive participants
Among anti-SARS-CoV2 seropositive participants, the percentage of asymptomatic participants will be determined. COVID-19 symptoms will be measured using a questionnaire.
Time frame: Day 0
Agreement between the anti-SARS-CoV2 serological results obtained using two different techniques (detecting the presence of different antibodies)
The serological results obtained using the reference ELISA test results (detecting the presence of IgG and IgM antobodies) and using a second ELISA test detecting the presence of antibodies specifically directed against the Receptor Binding Domain and the Spike protein trimer of SARS-CoV2 virus will be compared.
Time frame: Day 0
Proportion of serum neutralization positive
Among anti-SARS-CoV2 seropositive participants, the percentage of participants with a positive response to serum neutralization will be determined.
Time frame: Day 0
Change of antibody level over time
The evolution of the antibody level over time will be determined using repeated serodiagnoses at 3 and 9 months.
Time frame: 3 months and 9 months after Day 0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.